Furthermore, as the NLRP1 pathway is silenced in skin cancer [113], pharmacological activation of NLRP1 in affected skin lesions, for example by talabostat, might represent a successful approach for the treatment of skin cancer patients. This evidence concerns the gene NLRP1 and skin cancer.